LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NAMS
NewAmsterdam Pharma Company N.V.
There isn't enough reported data to score NAMS yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NAMS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
NAMS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NAMS PE Valuation
NAMS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NAMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NAMS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NAMS on earnings quality, reporting a profit while its opponent remains loss making.
NAMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.68 | +$0.33 |
| Q2 2026 | -$2.15 | -$0.57 |
| Q1 2026 | -$1.78 | +$0.06 |
| Q4 2025 | -$1.72 | +$0.84 |
| Q3 2025 | -$2.01 | +$0.16 |
| Q2 2025 | -$1.58 | +$0.97 |
| Q1 2025 | -$1.84 | +$0.73 |
| Q4 2024 | -$2.56 | -$0.58 |
NAMS is still losing money, but far less than before: $1.68 per share over the past year, against $3.66 at its worst in late 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NAMS on profitability, with a higher operating margin.
NAMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.2M | +5407% |
| Q2 2026 | $3.7M | -81% |
| Q1 2026 | $3M | +2.1% |
| Q4 2025 | $32K | -100% |
| Q3 2025 | $348K | -99% |
| Q2 2025 | $19.1M | +740% |
| Q1 2025 | $3M | +113% |
| Q4 2024 | $12.8M | +1491% |
NAMS's revenue is recovering but still below its 2022 peak: $19M last quarter, up 5407% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -231% | +15615 points |
| Q2 2026 | -1753% | -1567 points |
| Q1 2026 | -1922% | +393 points |
| Q4 2025 | -206188% | -205849 points |
| Q3 2025 | -15846% | -15760 points |
| Q2 2025 | -186% | +2121 points |
| Q1 2025 | -2314% | +1646 points |
| Q4 2024 | -338% | +6022 points |
NAMS's operating margin was −231% last quarter, up 15615 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NAMS on cash generation, producing positive trailing cash flow while its opponent burns cash.
NAMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40M | -$7.1M |
| Q2 2026 | -$39.3M | -$1.5M |
| Q1 2026 | -$30.6M | +$5.8M |
| Q4 2025 | -$41M | -$3.5M |
| Q3 2025 | -$32.8M | -$20.2M |
| Q2 2025 | -$37.8M | +$16.4M |
| Q1 2025 | -$36.5M | +$18.5M |
| Q4 2024 | -$37.5M | -$4.4M |
NAMS has burned cash in almost every quarter: −$151M over the past year, against −$145M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NAMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NAMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +766K shares |
| 1 year | +4.3% | +5.1M shares |
| 3 years | +51% | +41.7M shares |
| 5 years | +44% | +38M shares |
NAMS has 124M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NAMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -55.9x | Net Cash |
| Q2 2022 | -2.7x | Net Cash |
| Q1 2022 | -16.5x | Net Cash |
NAMS has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NAMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 10.1 | Oversold |
NAMS's weekly RSI is 34 (neutral) and its Stochastic is 10 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NAMS PE vs Healthcare Sector
| Metric | NAMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NAMS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NAMS on trend strength, trading above more of its moving averages.
NAMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.7 | 3.7% below |
| 20 week MA | $25.2 | 21% below |
| 50 week MA | $30.0 | 33% below |
| 100 week MA | $27.3 | 27% below |
| 200 week MA | $21.4 | 6.6% below |
NAMS is in a downtrend: it's below all five of its weekly moving averages, and 6.6% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NAMS on returns for 2026, with the stronger performance.
NAMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.6 | $9.74 | -8.5% |
| 2022 | $9.74 | $11.3 | +16% |
| 2023 | $11.3 | $11.2 | -1.2% |
| 2024 | $11.2 | $25.9 | +132% |
| 2025 | $25.9 | $35.3 | +36% |
| 2026 YTD | $35.3 | $20.0 | -43% |
NAMS is down 43% so far in 2026, after finishing higher in three of the previous five years.